Postpartum Hemorrhage Treatment Market: By Drug Type (Oxytocin, Prostaglandins (Dinoprostone, Misoprostol), Ergot Alkaloids (Ergometrine, Methyl Ergonovine), Tranexamic acid, Pabal, Carboprost, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography.  

Purchase Option

$ 4400
$ 6600
$ 8900

Postpartum hemorrhage treatment market size was valued at USD 802.34 in 2022, growing at a CAGR of 5.3% during the forecast period 2023-2029. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol. Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.

Postpartum Hemorrhage Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.3%

Largest Market

Europe

Fastest Growing Market

North America
Postpartum Hemorrhage Treatment Market Dynamics

Drivers: The Support from healthcare organizations, Rising pregnancy complications. Restraints: Dearth of trained healthcare providers, High cost of the devices.

Postpartum Hemorrhage Treatment Market Segmentation

By Drug Type
  • Oxytocin
  • Prostaglandins (Dinoprostone, Misoprostol)
  • Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
  • Tranexamic acid
  • Pabal
  • Carboprost
  • Others
By Route Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The postpartum hemorrhage treatment market key players are: Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Pfizer, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Ferring B.V. (Switzerland), Cipla Inc. (India)

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The postpartum hemorrhage treatment market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2. Global Postpartum Hemorrhage Treatment Market Introduction 
2.1.Global Postpartum Hemorrhage Treatment Market  - Taxonomy
2.2.Global Postpartum Hemorrhage Treatment Market  - Definitions
2.2.1.Drug Type
2.2.2.Route Administration
2.2.3.Distribution Channel
2.2.4.Region
3. Global Postpartum Hemorrhage Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Postpartum Hemorrhage Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Postpartum Hemorrhage Treatment Market  By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Oxytocin
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Prostaglandins (Dinoprostone, Misoprostol)
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Tranexamic acid
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Pabal
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Carboprost
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Others
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
6. Global Postpartum Hemorrhage Treatment Market  By Route Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Postpartum Hemorrhage Treatment Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Postpartum Hemorrhage Treatment Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Oxytocin
9.1.2.Prostaglandins (Dinoprostone, Misoprostol)
9.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
9.1.4.Tranexamic acid
9.1.5.Pabal
9.1.6.Carboprost
9.1.7.Others
9.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Oxytocin
10.1.2.Prostaglandins (Dinoprostone, Misoprostol)
10.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
10.1.4.Tranexamic acid
10.1.5.Pabal
10.1.6.Carboprost
10.1.7.Others
10.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
 
11. Asia Pacific (APAC) Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Oxytocin
11.1.2.Prostaglandins (Dinoprostone, Misoprostol)
11.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
11.1.4.Tranexamic acid
11.1.5.Pabal
11.1.6.Carboprost
11.1.7.Others
11.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Oxytocin
12.1.2.Prostaglandins (Dinoprostone, Misoprostol)
12.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
12.1.4.Tranexamic acid
12.1.5.Pabal
12.1.6.Carboprost
12.1.7.Others
12.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Oxytocin
13.1.2.Prostaglandins (Dinoprostone, Misoprostol)
13.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
13.1.4.Tranexamic acid
13.1.5.Pabal
13.1.6.Carboprost
13.1.7.Others
13.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG (Switzerland)
14.2.2.Fresenius Kabi AG (Germany)
14.2.3.Pfizer, Inc. (U.S.)
14.2.4.GlaxoSmithKline Plc (U.K.)
14.2.5.Ferring B.V. (Switzerland)
14.2.6.Cipla Inc. (India)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Novartis AG (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Ferring B.V. (Switzerland)
  • Cipla Inc. (India)

Adjacent Markets